Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 (ProPAC-COVID)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04322396 |
Recruitment Status :
Completed
First Posted : March 26, 2020
Last Update Posted : February 15, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Virus Diseases Infection Viral Corona Virus Infection | Drug: Azithromycin Drug: Hydroxychloroquine Drug: Placebo oral tablet | Phase 2 |
In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still sparse data in the course, risk of various complications, and in particular how patients who are hospitalized are best treated to ensure high survival and short hospitalization. Despite the rapid spread of the disease globally, there is no solid data yet to recommend any specific treatments, which is why symptomatic, organ supportive therapy including respiratory therapy in acute pulmonary failure is recommended. There has been reported a high incidence of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a higher risk of dying because of septic shock. Thus, there is an urgent need for treatment that can improve the patient's chance of the shortest hospitalization possible, and treatment that can lower the risk of secondary infection and death.
This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during hospitalization. The aim of the study is to investigate whether the treatment can shorten hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care Units and death.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 117 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19 |
Actual Study Start Date : | April 6, 2020 |
Actual Primary Completion Date : | February 2, 2021 |
Actual Study Completion Date : | February 2, 2021 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Control
This arm will receive standard care and placebo in 15 days.
|
Drug: Placebo oral tablet
Placebo Azithromycin Drug: Placebo oral tablet Placebo Hydroxychloroquine |
Active Comparator: Intervention
This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.
|
Drug: Azithromycin
Azithromycin Drug: Hydroxychloroquine Hydroxychloroquine |
- Number of days alive and discharged from hospital within 14 days [ Time Frame: 14 days ]
- Categorization of hospitalization status [ Time Frame: 14 days ]
The patient will becategorized into one of the following 8 categories depending on status of their hospitalization:
- Dead (yes/no)
- Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no)
- Hospitalized and receiving Non-invasive ventilation or "high-flow oxygen device" (yes/no)
- Hospitalized and given oxygen supplements different from (2) and (3) (yes/no)
- Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no)
- Hospitalized for observation (yes/no)
- Discharged from hospital with restriction of activity level (yes/no)
- Discharged from hospital without any restrictions of activity level (yes/no)
Only one category can be "yes".
- Admitted to intensive care unit, if admitted to ICU then length of stay [ Time Frame: 14 days ]
- Have used Non-invasive ventilation (NIV) during hospitalization [ Time Frame: 14 days ]
- Mortality [ Time Frame: 30 days ]
- Length of hospitalization [ Time Frame: 14 days ]
- Days alive and discharged from hospital [ Time Frame: 30 days ]
- Mortality [ Time Frame: 90 days ]
- Mortality [ Time Frame: 365 days ]
- Number of readmissions (all causes) [ Time Frame: 30 days ]
- Number of days using non-invasive ventilation (NIV) [ Time Frame: 14 days ]
- Change in patient's oxygen partial pressure [ Time Frame: 4 days ]Delta PaO2 measured in arterial puncture
- Change in patient's carbondioxid partial pressure [ Time Frame: 4 days ]Delta PaCO2 measured in arterial puncture
- Level of pH in blood [ Time Frame: 4 days ]pH measured in arterial puncture
- Time for no oxygen supplement (or regular oxygen supplement "LTOT") [ Time Frame: 14 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient admitted to a Danish emergency department, lung medical department or medical department
- Age >18 years
- Hospitalized <48 hours
- Positive COVID-19 test/diagnosis during the hospitalization
- Signes informed consent
Exclusion Criteria:
- If the patient uses > 5 LO2/min at time of recruitment
- Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates
- Pregnancy
- Breatfeeding
- Neurogenic hearing loss
- Psoriasis
- Retinopathy
- Maculopathy
- Changes in vision field
- Severe liver disease other than amoebiases
- Severe gastrointestinal, neurological or haematological disorders
- eGFR < 45 ml/min/1.73m2
- Clinically significant cardiac conduction disorders/arrhytmias or prolonged QTc interval
- Myasthenia Gravis
- Uses Digoxin
- Glucose-6-phosphate dehydrogenase defiency
- Porphyria
- Hypoglycemia at any time since hospitalization
- Severe mental illness which significantly impedes cooperation
- Severe linguistic problems that significantly impedes cooperation
- Treatment with sickle alkaloids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04322396
Denmark | |
Aalborg Sygehus | |
Aalborg, Denmark | |
Bispebjerg Hospital | |
Copenhagen, Denmark | |
Herlev-Gentofte Hospital | |
Copenhagen, Denmark | |
Hvidovre Hospital | |
Copenhagen, Denmark | |
Nordsjællands Hospital | |
Hillerød, Denmark | |
Odense Universitetshospital | |
Odense, Denmark | |
Roskilde Sygehus | |
Roskilde, Denmark | |
Slagelse Sygehus | |
Slagelse, Denmark |
Responsible Party: | Chronic Obstructive Pulmonary Disease Trial Network, Denmark |
ClinicalTrials.gov Identifier: | NCT04322396 |
Other Study ID Numbers: |
KronLungesyg_COVID_19_protokol |
First Posted: | March 26, 2020 Key Record Dates |
Last Update Posted: | February 15, 2021 |
Last Verified: | February 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Infection Communicable Diseases Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Coronaviridae Infections Nidovirales Infections RNA Virus Infections Respiratory Tract Infections Respiratory Tract Diseases |
Azithromycin Hydroxychloroquine Anti-Bacterial Agents Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antirheumatic Agents |